Beosin vs Immunefi

Overview

Beosin Beosin is a Web3 security provider offering smart contract auditing, on-chain monitoring, and vulnerability scanning, with support for Solana programs. It spans both pre-deployment audits and post-dep... Immunefi Immunefi is Web3's leading bug-bounty and security-services platform, protecting over $190 billion in user funds across the industry. It connects protocols with the whitehat researcher community. Sec...

Community Ratings

Immunefi is rated higher by the MadeOnSol community with 5.0/5 stars across 2 reviews, compared to 4.0/5 for Beosin (1 review). That said, ratings only tell part of the story — what matters most is which tool fits your specific workflow.

Pricing & Value

Beosin uses a paid model, while Immunefi is freemium.

Key Features

Beosin offers 5 features including Smart contract auditing for Solana programs, On-chain monitoring and real-time threat alerts, Automated vulnerability scanning, and 2 more. Immunefi counters with 5 features including Leading Web3 bug-bounty platform, Protects $190B+ in user funds, Rewards for disclosing vulnerabilities in Solana programs, and 2 more. The right choice depends on which specific features matter for your use case — check the individual review pages for full breakdowns.

Reliability & Health

We monitor both tools around the clock for uptime, SSL validity, and response times. Beosin currently has a healthy health status with 99.0% uptime over the last 30 days. Immunefi is rated healthy with 100.0% uptime. For any tool you trust with your funds, trades, or yield, uptime and speed are non-negotiable.

Strengths

Beosin's key strengths include covers the full security lifecycle, not just audits, combines manual review with automated analysis, real-time monitoring catches post-launch threats. Immunefi stands out for continuous security beyond one-time audits, aligns incentives with whitehat researchers, industry-leading scale and payouts. On the flip side, Beosin's weaknesses include b2b security service, not an end-user tool, while Immunefi's main drawback is for protocol teams and researchers, not end users.